Journal articleCancer Res2018
Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer.
- Journal
- Cancer Res
- Published
- 25 September 2018
- Citations
- 102
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 2
- Its registry lists this paper as resultsGemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I NCT01852890↗
- BackgroundA Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients NCT03541486↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.
Grants 4
- Mechanisms of pharmacological ascorbate inhibition of pancreatic cancer metastases I01BX001318↗
- Project 1: Inhibition of Metastasis Utilizing Pharmacological Ascorbate in Pancreas Cancer P01CA217797↗
- Cancer Center Support Grant (CCSG) P30CA086862↗
- Pharmacological Ascorbate as a Radiosensitizer in Pancreatic Cancer R01CA184051↗